G Medical Innovations’ CEO Yacov Geva Pumps In More Cash To Fund Company’s Growth

  • Oct 31, 2018 AEDT
  • Team Kalkine
G Medical Innovations’ CEO Yacov Geva Pumps In More Cash To Fund Company’s Growth

The chief executive officer and president of G Medical Innovations’ (ASX: GMV) Yacov Geva has pumped in his personal cash into the company worth US$10 million in the form of loan this time. Earlier also he had provided an amount of US$3 million to support the company for its growth and expansion plan which also includes the working capital, inventory as well as the medical devices.

The loan has increased from US$3 million to US$10 million at an annual interest of 10%. It was also agreed that the company will repay the loan fully as per its own choice. The board of the company commented that the terms and condition laid down by Mr. Geva is much better than the other financing options available to the company from the commercial lenders.

Also, the loan sanctioned to the company is on “arms’ length terms”. Mr. Geva agreed to give loan to the company based on New York based MEF I. It had bought US$3.25 million convertible securities at the rate of US$1.10 each. 

The company has enhanced its cash reserves after the announcement about the regulatory approvals from the US Food and Drug Administration (FDA), European CE (CE) and China Food and Drug Administration (CFDA) for its China processing facility.

After the 2 months of independent auditing of the G Medical’s production facility in Guangzhou, the company got approval for its China processing facility. As per the company, the approval of China processing facility will facilitate its global production capacity.

The approvals from CE, FDA and CFDA is itself a proof of high-quality of our production facility as well as the strong relationships within the country.

Within a stipulated timeframe, the company is committed to achieve a major milestone. Mr. Geva also states that the company is focused in meeting the demand from their global partnership and also execute the commercial plans as soon as possible.

G Medical was able to protect its FDA approval for more than 48 medical devices of the company.  These devices comprises of mobile sensors to monitor a range of vital signs such as temperature, body positioning, electrocardiography, blood oxygen levels and heart rate.

In order to facilitate vital sign data to get generated, stored, shared and analyzed, the company has associated its Prizma medical smartphone case to a software platform.

The medical devices of G Medical’s will be catering into several regions of the world which includes the US, Europe, China and Japan. There was a positive reaction of the investors after this news and the share price of the company went up by 17% to reach $0.40 this morning.

The current market price of the share is A$0.375 with a market A$121.3 million. Also, as per the chart, we see that the moving average convergence line is below the signal line and it tend to cut the line from below the signal line.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.



All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK